Wei-Chen Lu
Overview
Explore the profile of Wei-Chen Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen P, Chen C, Chang S, Chang Y, Lin B, Chen H, et al.
Am J Cancer Res
. 2025 Jan;
14(12):5863-5873.
PMID: 39803657
This multicenter study explored the survival benefits of upfront primary tumor resection (PTR) followed by first-line cetuximab plus chemotherapy in real-world patients with wild-type metastatic colorectal cancer (mCRC). Treatment options...
2.
Yang M, Chen T, Wang H, Hsieh J, Huang H, Hsieh M, et al.
BMC Cancer
. 2024 Oct;
24(1):1227.
PMID: 39369189
Background: In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we...
3.
Huang J, Lu W, Lee B
Case Rep Oncol Med
. 2024 May;
2024:7925511.
PMID: 38770355
Delayed migration and exposure of embolic coils is a rare complication of endovascular therapy for carotid blowout syndrome. A 64-year-old man with recurrent tongue cancer noticed the presence of foreign...
4.
Lu H, Hsieh M, Wang H, Hsieh J, Yen C, Wu S, et al.
Head Neck
. 2024 Feb;
46(5):1063-1073.
PMID: 38385970
Background: For R/M HNSCC, the differences in prognosis and treatment options between distant metastasis (DM) and locoregional recurrence, especially in the DM group, remain unclear. Methods: From the Taiwan Head...
5.
Wang H, Lou P, Yang M, Chen T, Lien M, Lin J, et al.
Target Oncol
. 2024 Jan;
19(1):51-58.
PMID: 38285067
Background: Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although...
6.
Chen H, Kuo Y, Chen C, Chang C, Wang S, Chien Y, et al.
Oncologist
. 2024 Jan;
29(4):e498-e506.
PMID: 38227604
Objective: Reports of tuberculosis (TB) during anticancer treatment with immune checkpoint inhibitors (ICIs) are increasing. However, it is not clear whether the use of ICIs is a significant risk factor...
7.
Chen C, Chang S, Chang Y, Lin B, Chen H, Hsieh Y, et al.
Am J Cancer Res
. 2024 Jan;
13(12):6333-6345.
PMID: 38187069
This multicenter study aimed to explore the survival benefit of metastasectomy by first-line cetuximab-based chemotherapy in real-world patients with wild-type metastatic colorectal cancer (mCRC). The primary endpoints were overall survival...
8.
Chang Y, Chen C, Chang S, Chang Y, Lin B, Chen H, et al.
Nutrients
. 2023 Jul;
15(13).
PMID: 37447297
Malnutrition is a common problem in patients with metastatic colorectal cancer (mCRC) receiving targeted therapy plus chemotherapy, resulting in severe toxicity and decreased survival rates. This retrospective study employing propensity...
9.
Lu W, Pringa E, Chou L
Magnes Res
. 2017 Sep;
30(2):42-52.
PMID: 28869207
Biomaterials containing magnesium are used for implants and bone regeneration. However, mechanisms underlying the biologic effects of magnesium are still largely unknown and have not been examined on normal human...